Recent studies have suggested that metastatic PCa patients with germline MMR pathogenic variants may have a particular sensitivity to hormonal therapies, as well as a possible response to PD−1 inhibitors [76]. This evidence concerns the gene MRC1 and posterior cortical atrophy.